Results 101 to 110 of about 20,740 (205)

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance [PDF]

, 2011
Background The BCR-ABL1 translocation occurs in chronic myeloid leukemia (CML) and in 25% of cases with acute lymphoblastic leukemia (ALL). The advent of tyrosine kinase inhibitors (TKI) has fundamentally changed the treatment of CML.
Hilmar Quentmeier, Sonja Eberth, Julia Romani, Margarete Zaborski, Hans G Drexler   +4 more
core   +2 more sources

Phosphorylation activity and specificity of the oncogenic tyrosine kinase fusion protein BCR/ABL

, 2021
Tyrosinphosphorylierung (pTyr) ist ein zentraler Bestandteil vieler zellulärer Signalpfade und ihre Deregulation führt zu Krebserkrankungen wie Leukämie. Kinase-Substrat-Annotation ist unerlässlich um das Krankheitsbild zu verstehen. Diese wird jedoch von Kinasenredundanz, Spezifitätsüberlappung und Aktivitätsdifferenzen erschwert.Das ...
openaire  

Novel prognostic factors in chronic myeloid leukemia [PDF]

, 2008
Chronic myeloid leukemia (CML) is a malignant clonal blood disease that originates from a pluripotent hematopoietic stem cell. The cytogenetic hallmark of CML, the Philadelphia chromosome (Ph), is formed as a result of reciprocal translocation between ...
Lundán, Tuija
core  

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR

Iatreia, 2014
Introduction: Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), resulting from the balanced reciprocal translocation t(9;22)(q34;q11).
Aya Bonilla, Carlos Alberto , Domingo Torres, José , Muskus, Carlos Enrique, Ramírez Gaviria, Gloria , Cuervo Sierra, Jorge , Sierra Sánchez, Margarita , Cuéllar-Ambrosi, Francisco , Botero Garcés, Jorge Humberto, Gloria Artigas A., Carmen , Muñetón, Carlos Mario , Vásquez Palacio, Gonzalo   +10 more
doaj  

Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer [PDF]

ACS Medicinal Chemistry Letters, 2020
openaire   +2 more sources

The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients [PDF]

, 2001
Background and Objectives. Detection of PML-RAR alpha transcripts by RT-PCR is now established as a rapid and sensitive method for diagnosis of acute promyelocytic leukemia (APL), Although the majority of patients in longterm clinical remission are ...
Carrara, P, de Sousa, AB, Diamond, J, Foroni, L, Gameiro, P, Guimaraes, JE, Hoffbrand, AV, Mehta, AB, Parreira, A, Prentice, HG, Silva, AL, Vieira, S   +11 more
core  

Молекулярно-генетическая диагностика минимальной остаточной болезни в онкогематологии [PDF]

, 2014
лейкозГЕМАТОЛОГИЧЕСКИЕ НОВООБРАЗОВАНИЯГЕННАЯ ЭКСПРЕССИЯГЕНЕТИЧЕСКИЕ ...
Семенов, В. М., Шляхтунов, Е. А.   +1 more
core  

Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases

, 2016
B Acute Lymphoblastic leukemia (B-ALL) with Philadelphia chromosome (Ph') is a neoplasm of lymphoblast committed to the B cell lineage. The clinical presentation of B-ALL Ph'+ is similar to B-ALL, but is more common in adults than in children. The e1a3 rare variant is produced by the fusion of BCR exon 1 to ABL exon 3.
Lopez-Andrade, Bernardo, Gutierrez, Antonio, Garcia, Lucia, Cunill, Vanesa, Duran Pastor, Maria Antonia, Sampol Mayol, Antonia, Bernues, Marta, Iglesias, Julio, Ramos-Asensio, Rafael, Llado, Josep, Sanchez, Maria, Carlos Amat, Juan, Martinez-Serra, Jordi   +12 more
openaire   +1 more source

Cell cycle control and cancer [PDF]

, 2018
This review consists of two parts. In the first part normal mechanisms regulating the progression of cells through the cell cycle are briefly reviewed. Besides mitogenic stimulation, cyclin kinase inhibition, the G1 restriction point and the prb pathway,
Wagner, Hans
core  

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.

Haematologica, 2006
Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic protein required for neoplasia. We have shown in phase I and II trials that a tumor-specific, bcr-abl-derived peptide vaccine can be safely administered to patients with ...
Javier, Pinilla-Ibarz, Tatyana, Korontsvit, Victoriya, Zakhaleva, Wendy, Roberts, David A, Scheinberg   +4 more
openaire   +1 more source